<DOC>
	<DOCNO>NCT01569035</DOCNO>
	<brief_summary>This study examine use oral anti coagulant warfarin management unexplained oligohydramnios improve perinatal outcome little complication mother neonate .</brief_summary>
	<brief_title>Warfarine Unexplained Oligohydramnios</brief_title>
	<detailed_description>A randomize control study 200 pregnant woman idiopathic oligohydramnios 28 32 week . Women randomize receive 3 mg warfarin daily ( Warfarin group ) placebo ( Placebo group ) . Outcomes include amniotic fluid index ( AFI ) , duration pregnancy perinatal outcomes include Apgar score , Neonatal intensive care admission ( NICU ) . Patients eligible inclusion 28t 32 week pregnancy age 18-35 year diagnose idiopathic oligohydramnios exclude medical history detail u/s examination , cut AFI le 5cm . A write informed consent take . Gestational age determine basis last menstrual period , confirm ultrasound scan conduct 6 14 week gestation The clinical work-up include history take prior enrollment , examination , obstetric ultrasound evaluation , biophysical profile take 32 week pregnancy Exclusion criterion chronichypertension , anaemia , cardiac disease , history premature rupture membrane structural malformation . Sterile speculum examination do exclude rupture membrane . Detailed level 2D ultrasonography determine possible etiology exclude multiple pregnancy fetal death . All fetus alive fetal weight prior treatment follow visit . Doppler ultrasound uterine , umbilical middle cerebral artery , fetal ascend aorta do use resistant index ( RI ) , pulsetilty index ( PI ) systolic/diastolic ( S/D ) ratio follow visit . Laboratory test obtain include complete blood picture , liver function test , immunological test exclude antiphospholipid antibody do . After patient unknown major cause classify idiopathic oligohydramnios treatment start . The patient randomly allocate 2 treatment group use computer-generated number seal envelope . Treatment start immediately test result know , continue 36 complete week pregnancy active onset labor . The patient randomize receive either daily dose 3 mg warfarin oral tablet daily placebo sachet The placebo sachets especially manufacture look identical warfarin tablet . The tablet place sac store envelope number 1 200 The envelope number randomized accord computer-generated randomization table ensure equal number patient arm . Throughout trial , access randomization code available pharmacist manufacture placebo pack envelope available treat physician patient Treatment protocol : One tablet 3 mg warfarin provide daily patient Warfarin group placebo Placebo group . After start treatment ; weekly follow patient four week till 36 week 2 week thereafter . Each follow visit follow do ; assessment amniotic fluid , biophysical profile include non stress test ( NST ) , Doppler U/S fetal ascend aorta , uterine , middle cerebral umbilical artery . Laboratory measurement prothrombine time concentration INR check daily therapeutic range 2 consecutive day , twice week 1-2 week , weekly stable . Change patient 's condition , e.g . liver disease , intercurrent illness , new drug start necessitates frequent test . Patients advise report bruise bleed immediately , advise , avoid aspirin use paracetamol pain , avoid contact sport activity carry risk head injury . During labor cesarean section visual inspection blood loss 48 hour follow occurrence hematoma neonatal follow bleeding problem . Discontinuation treatment do two week treatment change amniotic fluid , manifestation fetal distress appear patient complete 36 week gestation . Assessment outcome measure The primary outcome improvement amniotic fluid improve biophysical profile . The secondary outcome prolongation pregnancy till suitable time fetal maturity . The baseline characteristic study participant analyze include amniotic fluid index , Doppler indices change fetal maternal vessles , mode delivery rate continuation pregnancy . Finally , maternal neonatal complication cost treatment calculate . Statistical analysis : . Data collect analyzed computer program SPSS version 17 Chicago -USA - Data express mean ± S.D , number percentage - Using Paried t.test determine significance numeric variable - Using Pearson´s correlation determine significance variable N.S= P &gt; 0.05 No significance - = P &lt; 0.05 Significant .</detailed_description>
	<mesh_term>Oligohydramnios</mesh_term>
	<mesh_term>Coagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Patients eligible inclusion 28th 32nd week pregnancy age 1835 year diagnose idiopathic oligohydramnios exclude medical history detail u/s examination , cut AFI le 5cm Exclusion criterion chronic hypertension , anaemia , cardiac disease , history premature rupture membrane structural malformation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>oligohudramnios</keyword>
	<keyword>oral anti coagulant</keyword>
	<keyword>Dopplar ultrasound</keyword>
</DOC>